Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Work
Year: 2022
Type: article
Abstract: DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients... more
Source: Cancer Discovery
Institutions Centre Hospitalier Universitaire de Liège, Samsung Medical Center, Kanagawa Prefectural Hospital Organization, Kanagawa Cancer Center, University of California, Los Angeles +19 more
Cites: 27
Cited by: 74
Related to: 10
FWCI: 15.56
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
Funder American Regent
Grant ID NA